Technical Analysis for CMRX - Chimerix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 0.92 | 0.60% | 0.01 |
Earnings due: May 2
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New Downtrend | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.60% | |
Below Lower BB | Weakness | 0.60% | |
Down 3 Days in a Row | Weakness | 0.60% | |
Lower Bollinger Band Touch | Weakness | 0.60% | |
Oversold Stochastic | Weakness | 0.60% | |
20 DMA Resistance | Bearish | -4.23% |
Alert | Time |
---|---|
Possible NR7 | about 10 hours ago |
Up 2% | about 12 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Rose Above Lower Bollinger Band | about 12 hours ago |
Up 1% | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/02/2024
Chimerix, Inc. Description
Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Hematopoietic Stem Cell Herpes Papillomavirus Ebola Monkeypox Prodrugs Poxviruses Antivirals Cytomegalovirus Infection Orthopoxvirus
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.57 |
52 Week Low | 0.88 |
Average Volume | 470,782 |
200-Day Moving Average | 1.03 |
50-Day Moving Average | 1.07 |
20-Day Moving Average | 0.99 |
10-Day Moving Average | 0.99 |
Average True Range | 0.06 |
RSI (14) | 34.21 |
ADX | 25.24 |
+DI | 12.11 |
-DI | 26.28 |
Chandelier Exit (Long, 3 ATRs) | 0.99 |
Chandelier Exit (Short, 3 ATRs) | 1.08 |
Upper Bollinger Bands | 1.07 |
Lower Bollinger Band | 0.92 |
Percent B (%b) | 0.01 |
BandWidth | 15.38 |
MACD Line | -0.04 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.009 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.98 | ||||
Resistance 3 (R3) | 0.98 | 0.96 | 0.97 | ||
Resistance 2 (R2) | 0.96 | 0.94 | 0.96 | 0.97 | |
Resistance 1 (R1) | 0.94 | 0.94 | 0.95 | 0.94 | 0.96 |
Pivot Point | 0.92 | 0.92 | 0.93 | 0.92 | 0.92 |
Support 1 (S1) | 0.90 | 0.90 | 0.91 | 0.90 | 0.88 |
Support 2 (S2) | 0.88 | 0.90 | 0.88 | 0.87 | |
Support 3 (S3) | 0.86 | 0.88 | 0.87 | ||
Support 4 (S4) | 0.86 |